[PDF][PDF] Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

…, S Pérez-Rodríguez, M Rodriguez-González… - Med, 2022 - cell.com
Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

…, S Pérez-Rodríguez, M Rodriguez-González… - MedRxiv, 2022 - medrxiv.org
Background We report results of immunogenicity, safety and reactogenicity of SOBERANA
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.

ME Toledo-Romani, LV Sanchez, MR Gonzalez… - 2021 - pesquisa.bvsalud.org
… Maria Eugenia Toledo-Romani; Leslihana Verdecia Sanchez; Meybis Rodriguez
Gonzalez; Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; …

Safety and Immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.(preprint)

ME Toledo-Romani, LV Sanchez, MR Gonzalez… - 2021 - pesquisa.bvsalud.org
Background SOBERANA 02 is a COVID19 conjugate vaccine candidate based on SARS CoV2
recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimericRBD. …

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

…, S Perez-Rodriguez, M Rodriguez-Gonzalez… - 2022 - pesquisa.bvsalud.org
… Maria Eugenia-Toledo-Romani; Mayra Garcia-Carmenate; Leslyhana Verdecia-Sanchez;
Suzel Perez-Rodriguez; Meybis Rodriguez-Gonzalez; Carmen Valenzuela-Silva; Beatriz …

Real-World Effectiveness of the OBERANA02 and SOBERANA-Plus Vaccine Combination in Children 2 to 11 Years of Age during the SARS CoV-2 Omicron Wave in …

…, L Iniguez-Rojas, M Rodriguez-González… - 2023 - papers.ssrn.com
Background: Increased paediatric COVID-19 occurrence due to the SARS-CoV-2 0micron
variant raised concerns about the effectiveness of existing vaccines. Methods: In September …

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

…, S Pérez-Rodríguez, M Rodriguez-González… - 2022 - papers.ssrn.com
Background: SOBERANA 02 have been evaluated in phase I and IIa studies comparing
homologous vs. heterologous schedule (this one, including SOBERANA Plus). Here, we report …

[HTML][HTML] A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles

D Santana-Mederos, R Perez-Nicado, Y Climent… - RSC chemical …, 2022 - pubs.rsc.org
SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its
receptor-binding domain (RBD) with the host’s cellular receptor. Vaccines seek to block this …

[PDF][PDF] RSC Chemical Biology

YI Gonzalez, LA Espinosa, Y Ramos, LJ Gonzalez… - 2020 - hal.science
SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its
receptor-binding domain (RBD) with the host’s cellular receptor. Vaccines seek to block this …

[HTML][HTML] Memoria histórica de la Salud Pública en San Fernando de Camarones

M Martínez Roque, R Cazorla Pérez - MediSur, 2017 - scielo.sld.cu
El presente trabajo tiene como objetivo exponer la historia de la salud pública en San Fernando
de Camarones, la cual se remonta a la época en que vivieron los primitivos pobladores …